Loring Wolcott & Coolidge Fiduciary Advisors’s United Therapeutics UTHR Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-10	Closed	-$1K	–	766
2018 Q4	$1K	Hold	10	–	–	﹤0.01%	681
2018 Q3	$1K	Hold	10	–	–	﹤0.01%	644
2018 Q2	$1K	Hold	10	–	–	﹤0.01%	659
2018 Q1	$1K	Hold	10	–	–	﹤0.01%	711
2017 Q4	$1K	Hold	10	–	–	﹤0.01%	718
2017 Q3	$1K	Buy	+10	New	+$1.28K	﹤0.01%	749

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's UTHR Position: Q1 2019 in Review

Loring Wolcott & Coolidge Fiduciary Advisors sold out of United Therapeutics (UTHR) in Q1 2019, closing a stake of 10 shares — an estimated $1K sold.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in UTHR in Q3 2017 and held it in 6 quarters. The position peaked at $1K in Q4 2018. 378 funds tracked by Wall St. Rank hold UTHR as of Q1 2019.

Loring Wolcott & Coolidge Fiduciary Advisors reported no remaining United Therapeutics position as of Q1 2019 after selling out during the quarter.
Loring Wolcott & Coolidge Fiduciary Advisors sold 10 United Therapeutics shares in Q1 2019, an estimated $1K.
Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in United Therapeutics in Q3 2017 and held it in 6 quarters.
Loring Wolcott & Coolidge Fiduciary Advisors's United Therapeutics position peaked at $1K in Q4 2018.
378 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2019.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q1 2019, filed 8 Apr 2019.